
Lunit has acquired Prognosia, an AI-driven breast cancer risk prediction startup founded by WashU researchers, to accelerate clinical adoption of advanced mammography analytics.
Key Details
- 1Prognosia, co-founded by WashU Medicine researchers, uses AI-driven software to analyze mammograms for five-year breast cancer risk prediction.
- 2The software, Prognosia Breast, received FDA Breakthrough Device Designation in early 2024.
- 3Past research showed Prognosia's risk model is more than twice as accurate as standard questionnaire-based approaches.
- 4The technology performs well across diverse demographic groups and is compatible with both 2D mammography and 3D tomosynthesis imaging.
- 5Lunit aims to fast-track the technology’s journey to market by integrating it with existing clinical workflows.
- 6Founders will serve in advisory roles during FDA review and further development at Lunit.
Why It Matters

Source
EurekAlert
Related News

NYU AI Model Improves 5-Year Breast Cancer Risk Prediction via 3D Mammograms
NYU researchers developed an AI model using longitudinal 3D mammograms that outperforms single-scan and 2D-based tools in predicting 5-year breast cancer risk.

Study Reveals Only Three FDA-Cleared AI Devices Tested on Patient Outcomes
An analysis found that out of 1,357 AI-enabled medical devices cleared by the FDA, only three were actually tested for their effect on patient health outcomes.

AI-Driven Blood Test Shows Success in Early Liver Cancer Detection Across Populations
Researchers validate an AI-powered cfDNA blood test that detects liver cancer accurately across diverse populations, enhancing early detection efforts.